Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to $82000.0.

  • TriSalus Life Sciences' Cash from Financing Activities fell 9859.18% to $82000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $33.5 million, marking a year-over-year decrease of 429.9%. This contributed to the annual value of $37.9 million for FY2024, which is 3055.7% down from last year.
  • As of Q3 2025, TriSalus Life Sciences' Cash from Financing Activities stood at $82000.0, which was down 9859.18% from $20.7 million recorded in Q2 2025.
  • In the past 5 years, TriSalus Life Sciences' Cash from Financing Activities registered a high of $40.3 million during Q3 2023, and its lowest value of $43000.0 during Q4 2023.
  • Its 4-year average for Cash from Financing Activities is $9.1 million, with a median of $5.9 million in 2022.
  • As far as peak fluctuations go, TriSalus Life Sciences' Cash from Financing Activities plummeted by 9927.22% in 2023, and later skyrocketed by 686279.07% in 2024.
  • Over the past 4 years, TriSalus Life Sciences' Cash from Financing Activities (Quarter) stood at $5.9 million in 2022, then tumbled by 99.27% to $43000.0 in 2023, then skyrocketed by 6862.79% to $3.0 million in 2024, then plummeted by 97.26% to $82000.0 in 2025.
  • Its Cash from Financing Activities stands at $82000.0 for Q3 2025, versus $20.7 million for Q2 2025 and $9.7 million for Q1 2025.